About Michael Nagel

An experienced executive leader of emerging-growth medical technology companies, I am passionate about bringing new technologies to market efficiently by building high-functioning mission-oriented teams, creating a culture built on innovation and collaboration, and instilling long-view perspective.

High-functioning, mission-oriented teams:
Whether the challenge is to get to know and trust members of an existing team or to recruit key players to fill gaps, my diverse experience in the medical device industry and my ability to develop lasting trusted relationships serve me well in ensuring that we have the right people in the right seats.

Creating a culture built on innovation and collaboration:
I value intellectual curiosity and out-of-the-box thinking in myself and others. By role modeling active listening and recognizing that any team member can contribute a breakthrough idea, we begin to shape a culture that rewards innovative thinking and nimble response.

Long-view perspective:
As an endurance athlete and 7-time Ironman competitor, my mental focus helps others stay the course. Focusing on improved patient outcomes keeps us moving to our goal.
I am so proud of our team at Vomaris. Through our patented bioelectrical materials, we are literally defining the new gold standard for infection control and wound management. Prior to Vomaris, I served as Chief Commercial Officer (CCO) at Neomend and oversaw the commercial launch of the PMA device, ProGEL. Under my leadership, ProGEL sales grew to over 1,200 hospitals in just 36 months. The company was acquired by C.R. Bard.

I also served as co-founder and Vice President of Worldwide Sales and Marketing at Vascular Solutions. I helped take Vascular Solutions from inception to its initial public offering (IPO) within 39 months and led the launch of a novel, biological vascular closure device in the interventional marketplace. The company was sold to Teleflex for over $900 million. I also served as Vice President of Sales and Marketing at Incisive Surgical, which was acquired by Cooper Surgical.

My decades of leadership in the medtech industry have been diverse. I have worked across organ systems and disease states, from industry-leading companies to start-ups, and from mature products to those in the “napkin phase.” Recently I have been tapped for Board positions with a company that uses AI to guide the editing of genes for cancer treatment, and a company that is developing patented ultrasound heart catheters.